Merck & Co. (MRK)
(Delayed Data from NYSE)
$113.69 USD
+0.60 (0.53%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $113.60 -0.09 (-0.08%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$113.69 USD
+0.60 (0.53%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $113.60 -0.09 (-0.08%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth A Momentum B VGM
Zacks News
Pharma Stock Roundup: FDA Approves PFE & MRK's Oral Pills for COVID & Other Drugs
by Kinjel Shah
FDA approves Pfizer's (PFE) and Merck's (MRK) oral COVID antiviral pills and AstraZeneca's (AZN) asthma medicine, Tezspire (tezepelumab).
Top Stock Reports for Tesla, Adobe & Merck
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA), Adobe Inc. (ADBE), and Merck & Co., Inc. (MRK).
Pfizer (PFE) Gets FDA's Emergency Use Nod for COVID Pill
by Zacks Equity Research
Pfizer's (PFE) COVID-19 pill Paxlovid is the first oral antiviral medicine, which can be prescribed as an at-home treatment for mild-to-moderate COVID-19.
Stock Market News for Dec 23, 2021
by Zacks Equity Research
Wall Street closed higher on Wednesday completing back-to-back rallies after three-days of Omicron-led decline.
Merck (MRK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $76.16, marking a +0.82% move from the previous day.
Seagen (SGEN) Gets Positive CHMP Opinion for Bladder Cancer Drug
by Zacks Equity Research
The CHMP gives a positive opinion on, and recommends approval to Seagen's (SGEN) Padcev as a monotherapy for treating adult patients with locally advanced/metastatic urothelial cancer.
Pfizer (PFE) COVID Pill Paxlovid Gets CHMP Support in Europe
by Zacks Equity Research
The CHMP supports the use of Pfizer's (PFE) oral COVID-19 drug, Paxlovid, to treat high-risk patients even though it has not received conditional authorization from the European Commission.
Pharma Stock Roundup: PFE Announces Arena Buyout, LLY Ups 2021 View & More
by Kinjel Shah
Pfizer (PFE) offers to buy Arena Pharmaceuticals. Lilly (LLY) raises 2021 profit and sales outlook.
Merck (MRK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $75.91, marking a +0.82% move from the previous day.
Merck's (MRK) Pneumococcal Vaccine Vaxneuvance Gets EU Nod
by Zacks Equity Research
Merck's (MRK) Vaxneuvance includes pneumococcal serotypes 22F and 33F, which are not included in the currently licensed 13-valent conjugate vaccines.
Exelixis (EXEL) Initiates Study on XL092 in Advanced Solid Tumors
by Zacks Equity Research
Exelixis (EXEL) begins the dose-escalation stage of its study evaluating XL092 in combination with immuno-oncology therapies in patients with advanced solid tumors.
Should Invesco Defensive Equity ETF (DEF) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DEF
Pfizer (PFE) COVID Pill Maintains Strong Efficacy, Stock Up
by Zacks Equity Research
Pfizer's (PFE) COVID-19 pill maintains a substantial reduction in hospitalizations and deaths observed during interim analysis last month in the final analysis of the study data.
The Zacks Analyst Blog Highlights: Pfizer, Arena Pharma, Merck, Jazz Pharm and Sanofi
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Arena Pharma, Merck, Jazz Pharm and Sanofi
Bellus (BLU) Stock Surges on Data From Chronic Cough Study
by Zacks Equity Research
Bellus Health (BLU) achieves the primary endpoint in a phase IIb study evaluating BLU-5937 for the treatment of refractory chronic cough.
Merck's (MRK) HIV Studies on Islatravir Put on Clinical Hold
by Zacks Equity Research
With the FDA's clinical hold, no new studies can be initiated on Merck's (MRK) islatravir. While six studies on islatravir have been placed on full clinical hold, seven have been put on partial clinical hold.
Bristol-Myers (BMY) Up on Dividend Hike, Share Repurchase
by Zacks Equity Research
Bristol-Myers (BMY) increases its quarterly dividend and announces a share repurchase program. Consequently, the stock gains.
Does PFE, ARNA Deal Signal Robust Pharma M&A Activity in 2022?
by Kinjel Shah
The Pfizer (PFE)-Arena (ARNA) deal raises hopes that M&A activity will pick up significantly in 2022. as big drugmakers are sitting on huge piles of cash.
Is Hartford Multifactor Developed Markets exUS ETF (RODM) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RODM
Merck (MRK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $72.62, marking a -0.33% move from the previous day.
Pharma Stock Roundup: PFE Booster Works on Omicron, AZN COVID Cocktail Gets FDA Nod
by Kinjel Shah
Pfizer (PFE) and BioNTech's COVID-19 booster shot proves effective against the Omicron variant. FDA grants EUA to AstraZeneca's (AZN) cocktail antibody for pre-exposure prophylaxis (prevention) of COVID-19.
Markets Upbeat on Vaccine Efficacy Against Omicron Variant
by Zacks Equity Research
Markets Upbeat on Vaccine Efficacy Against Omicron Variant
Remedies for Omicron Apparent, Markets Up Again
by Mark Vickery
New forms of Covid-19 appear to be growing more highly infectious, if not necessarily more life-threatening.
Merck (MRK) Pauses Enrolment in HIV-1 Prevention Studies
by Zacks Equity Research
Merck (MRK) pauses enrolment for two phase III studies evaluating islatravir for pre-exposure prophylaxis of HIV-1 infection, following the recommendation of an external data monitoring committee.
Vaccine Stocks Down as Omicron May Not Be Too Severe
by Kinjel Shah
Stocks of Moderna (MRNA), BioNTech (BNTX), Novavax (NVAX) and Pfizer (PFE) decline as data suggests that Omicron variant may cause less severe cases of COVID-19.